Recent preclinical and clinical data also suggest that HER3 is involved in resistance to other HER receptor-targeted therapeutics [11–15]. Since HER3 has limited kinase activity, several newly developed monoclonal antibodies (mAbs) are being explored to target HER3 for cancer therapy. Patritumab ...